05), demonstrating neutrophil activation during hemodialysis. Less neutrophil activation occurs with peritoneal dialysis (
<0.05). Immunosuppressive treatment and anticoagulant therapy did not seem to affect the capacity of neutrophils to undergo activation with hemodialysis. Finally, levels of hemodialysis-induced neutrophil activation correlated with markers of endothelial activation (
= 0.44;
= 0.01).
Low sample size with heterogeneous patient cohort.
Neutrophil activation occurs during hemodialysis, potentially contributing to endothelial inflammation and damage. Neutrophil activation markers are novel and sensitive measures of biocompatibility for improving dialysis.
Neutrophil activation occurs during hemodialysis, potentially contributing to endothelial inflammation and damage. Neutrophil activation markers are novel and sensitive measures of biocompatibility for improving dialysis.
Depression is prevalent and highly associated with mortality among patients with chronic kidney disease (CKD). Psychological flexibility can be captured as acceptance in psychology, and its improvement by behavioral therapy is associated with reduced depression in some clinical settings. However, no study has been reported on patients with CKD. This study aimed to examine the association between psychological flexibility and depression in patients with CKD.
Cohort study.
This multicenter study of5 hospitals in Japan included patients withnondialysis stage 3-5 CKD or stage 5D CKD receiving hemodialysis or peritoneal dialysis.
Psychological flexibility measured using the 7-item Acceptance and Action Questionnaire (AAQ-II).
The prevalence and incidence of depression after 1 year, which was defined by a score≥16 points on the Center for Epidemiologic Studies Depression (CES-D) questionnaire.
Gamma regression was used in the examination of correlates of the psychological flexibility value. Modified Poiility was associated with lower prevalence and incidence of depression in patients with CKD. Further studies are warranted to determine the possible prevention and treatment of depression by the development of behavioral interventions to improve psychological flexibility.Kidney transplant recipients are at increased risk for infection, including coronavirus disease 2019 (COVID-19), given ongoing immunosuppression. In individuals with COVID-19, complications including thrombosis and endothelial dysfunction portend worse outcomes. Selleck 17-DMAG In this report, we describe a kidney transplant recipient who developed severe thrombotic microangiopathy with a low platelet count (12 ×109/L), anemia (hemoglobin, 7.5 g/dL with 7% schistocytes on peripheral-blood smear), and severe acute kidney injury concurrent with COVID-19. The clinical course improved after plasma exchange. Given this presentation, we hypothesize that COVID-19 triggered thrombotic microangiopathy.
Coronavirus disease 2019 (COVID-19) may be associated with high rates of acute kidney injury (AKI) and kidney replacement therapy (KRT), potentially overwhelming health care resources. Our objective was to determine the pooled prevalence of AKI and KRT among hospitalized patients with COVID-19.
Systematic review and meta-analysis.
MEDLINE, Embase, the Cochrane Library, and a registry of preprinted studies, published up to October 14,2020.
Eligible studies reported the prevalence of AKI in hospitalized patients with COVID-19 according to the Kidney Disease Improving Global Outcomes (KDIGO) definition.
We extracted data on patient characteristics, the proportion of patients developing AKI and commencing KRT, important clinical outcomes (discharge from hospital, ongoing hospitalization, and death), and risk of bias.
We calculated the pooled prevalence of AKI and receipt of KRT along with 95% CIs using a random-effects model. We performed subgroup analysis based on admission to an intensive care unit e estimates should help guide KRT resource planning.
AKI complicated the course of nearly 1 in 3 patients hospitalized with COVID-19. The risk for AKI was higher in critically ill patients, with a substantial number receiving KRT at rates higher than the general ICU population. Because COVID-19 will be a public health threat for the foreseeable future, these estimates should help guide KRT resource planning.Nucleic acids are relevant biopolymers in therapy and diagnosis, for which their purity and biological activity are of crucial relevance. However, these features are difficult to achieve by cost-effective methods. Herein, we report the functionalization of a macroporous chromatographic support functionalized with an ionic liquid (IL) with remarkable performance to purify nucleic acids. An initial screening with distinct IL chemical structures supported in silica was carried out, allowing to identify the IL 1-methyl-3-propylimidazolium chloride as the most promising ligand. A chromatographic macroporous matrix able to be used in preparative liquid chromatography was then functionalized and binding/elution studies were performed. The IL 1-methyl-3-propylimidazolium chloride acts as a multimodal ligand with a remarkable dynamic binding capacity. This macroporous support allows the (one-step) purification of nucleic acids, namely small RNAs, ribosomal RNA, and genomic DNA, from a bacterial lysate, and can be regenerated and reused without compromising its separation performance.
Biochemical markers, including GLOBE score and aspartate aminotransferase-to-platelet ratio index (APRI), are used to stratify risk in patients with primary biliary cholangitis (PBC). This study aimed to evaluate the effects of obeticholic acid (OCA) on categorical shifts in GLOBE score, APRI, and both combined, based on data from POISE, a phase III placebo-controlled trial in patients with PBC who had an incomplete response or were intolerant to ursodeoxycholic acid.
In a
analysis, baseline and Month 12 data from POISE were used to calculate the APRI and GLOBE score. Patients were stratified into 3 risk groups based on a combination of APRI (0.54) and GLOBE (0.3 or age-specific) thresholds.
The analysis included 215 patients (47 low risk; 79 moderate risk; 89 high risk). Using the combined GLOBE score (threshold of 0.3) and APRI thresholds, there was improvement in ≥1 risk stage in 37% and 35% of patients in the OCA 5-10 mg and 10 mg groups, respectively,
12% in the placebo group (both
<0.05).Selleck 17-DMAG
Top comments (0)